Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Cytotherapy. 2021 Aug;23(8):662-671. doi: 10.1016/j.jcyt.2020.12.007. Epub 2021 Feb 6.
Cellular therapies for malignant lymphoma include autologous or allogeneic hematopoietic stem cell transplantation (HSCT) and adaptive cellular therapy using EBV-specific T cells, cytokine-induced killer (CIK) cells, NKT cells, NK cells, chimeric antigen receptor T (CAR-T) cells and chimeric antigen receptor NK (CAR-NK) cells. In this review we discusses recent advances of these cellular therapies and consider ways to optimize these therapies. Not only a single strategy using one of these cellular therapies, but also multi-disciplinary treatment combines with antibodies, such as an anti-tumor antibody and an immune checkpoint antibody, may be more effective for relapsed and refractory lymphoma.
恶性淋巴瘤的细胞治疗包括自体或异基因造血干细胞移植（HSCT）和使用 EBV 特异性 T 细胞、细胞因子诱导的杀伤（CIK）细胞、NKT 细胞、NK 细胞、嵌合抗原受体 T（CAR-T）细胞和嵌合抗原受体 NK（CAR-NK）细胞的适应性细胞治疗。在这篇综述中，我们讨论了这些细胞治疗的最新进展，并考虑了优化这些治疗的方法。对于复发和难治性淋巴瘤，不仅需要使用这些细胞治疗中的一种的单一策略，而且还需要结合抗体的多学科治疗，例如抗肿瘤抗体和免疫检查点抗体，可能更有效。
